Mycophenolic Sodium Patent Expiration
Mycophenolic Sodium is Used for preventing organ rejection in patients who have received allogeneic renal transplants. It was first introduced by Novartis Pharmaceuticals Corp
Mycophenolic Sodium Patents
Given below is the list of patents protecting Mycophenolic Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Myfortic | US6306900 | Enteric coated pharmaceutical compositions |
Feb 27, 2018
(Expired) | Novartis |
| Myfortic | US6025391 | Enteric-coated pharmaceutical compositions of mycophenolate |
Apr 10, 2017
(Expired) | Novartis |
| Myfortic | US6172107 | Entric-coated pharmaceutical compositions |
Apr 10, 2017
(Expired) | Novartis |
Mycophenolic Sodium's Family Patents
Explore Our Curated Drug Screens
Mycophenolic Sodium Generic API Manufacturers
Several generic applications have been filed for Mycophenolic Sodium. The first generic version for Mycophenolic Sodium was by Apotex Inc and was approved on Aug 21, 2012. And the latest generic version is by Wanbang Biopharmaceuticals Inc and was approved on May 29, 2024.
Given below is the list of companies who have filed for Mycophenolic Sodium generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Aug 23, 2017 |
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Aug 23, 2017 |
2. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Sep 23, 2021 |
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Sep 23, 2021 |
3. AMTA
Amta Labs Ltd has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Amta.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Feb 10, 2021 |
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Feb 10, 2021 |
Manufacturing Plant Locations New
Amta's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Amta as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
4. APOTEX INC
Apotex Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Apotex Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Aug 21, 2012 |
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Aug 19, 2014 |
Manufacturing Plant Locations New
Apotex Inc's manufacturing plants are situated in 1 country - Canada. Given below are the details of these plant locations as well as the firm names of Apotex Inc as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| Canada |
| |||||||
5. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Feb 27, 2024 |
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Feb 27, 2024 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
6. BIOCON PHARMA
Biocon Pharma Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Biocon Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Nov 29, 2023 |
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Nov 29, 2023 |
Manufacturing Plant Locations New
Biocon Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Biocon Pharma as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
7. CONCORD BIOTECH LTD
Concord Biotech Ltd has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Concord Biotech Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Dec 13, 2019 |
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Dec 13, 2019 |
8. RK PHARMA
Rk Pharma Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Rk Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Jan 8, 2014 |
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Jan 8, 2014 |
Manufacturing Plant Locations New
Rk Pharma's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Rk Pharma as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
9. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 180MG BASE | tablet, delayed release | Discontinued | ORAL | N/A | Oct 30, 2014 |
| EQ 360MG BASE | tablet, delayed release | Discontinued | ORAL | N/A | Oct 30, 2014 |
10. TWI PHARMS
Twi Pharmaceuticals Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Twi Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | Nov 3, 2021 |
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | Nov 3, 2021 |
11. WANBANG BIOPHARMS
Wanbang Biopharmaceuticals Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Wanbang Biopharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 180MG BASE | tablet, delayed release | Prescription | ORAL | AB | May 29, 2024 |
| EQ 360MG BASE | tablet, delayed release | Prescription | ORAL | AB | May 29, 2024 |